Julie Hallet, Director of Research at the Canadian Society of Surgical Oncology (CSSO), shared a post on X:
“New marker for NF-PanNETs: BEND2 fusions by Aatur Singhi
7% of cases
DFS 13% at 3y
DSS 25% at 5y
ATRX-DAXX-BEND2 in 62% of met PanNETs
Great to add markers in heterogeneous PanNETs! Let’s keep eyes for clinical implications and use.”
Title: Recurrent BEND2 Fusion Genes Identified by Whole Transcriptome Sequencing of Non-Functional Pancreatic Neuroendocrine Tumors Correlate with Poor Patient Prognosis
Authors: Michelle A. Wood-Trageser, C. Tolson Nichols, Danielle A. Hutchings, Diana Bell, Abigail I. Wald, Katelyn Smith, Seung-Mo Hong, Claudio Luchini, Lodewijk A.A. Brosens, Anna Vera D. Verschuur, Michele Bevere, Rita T. Lawlor, Aldo Scarpa, Shannon Keating, James Tucker, Roderick J. O’Sullivan, Ta-Chiang Liu, Kevin McGrath, Kenneth Fasanella, Randall E. Brand, Anne Marie Lennon, Rohit Das, Harkirat Singh, Adam Slivka, Sultan Mahmood, Amy E. Hosmer, Asif Khalid, Stephanie L. Romutis, Amer H. Zureikat, Herbert J. Zeh, Melissa E. Hogg, Kenneth K. Lee, Alessandro Paniccia, Geoffrey Nunns, Melanie Ongchin, Walter G. Park, Patricio M. Polanco, Jin He, Diane M. Simeone, Cristina R. Ferrone, Dennis Hsu, Janie Zhang, Vikram Gorantla, John Rhee, Ralph H. Hruban, Anju H. Singhi, Sara A. Singhi, Candice K. Wang, Nuha Shaker, Robert Bubar, Maria Grupillo, Yi-Tak Lai, Marina N. Nikiforova, Christopher M. Heaphy, Kevin M. Waters, Aatur D. Singhi
More posts featuring Julie Hallet on OncoDaily.